31 Jul 2019
Funding will accelerate global commercial expansion of the company and support expanding product pipeline of prognostic tools
Cambridge Innovation Capital plc (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has participated in a £10 million Series B funding round in PredictImmune, a developer of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases. Cambridge Enterprise, University Venture Fund, Parkwalk and BGF also took part in the fundraise.
The investment cements PredictImmune’s strong financial position, enabling it to build on the successful launch of its first product, PredictSURE IBD™, with a major focus on continued commercial expansion across Europe, the USA and other territories in the coming months. It also allows the organisation to expand its product development activities – extending existing programmes in inflammatory bowel disease (IBD) as well as moving into a range of additional autoimmune areas including systemic lupus erythematosus (SLE). PredictImmune is aiming to build a portfolio of new products to complement and enrich its prognostic test pipeline in the coming years.
“We are thrilled to work with our colleagues at Cambridge Enterprise to support one of Cambridge’s most promising businesses. PredictImmune is at the forefront of personalised medicine, enabling improved treatment choices for patients with immune mediated diseases. We are especially excited about its lead product PredictSURE IBD™, which has the potential to end ‘trial-and-error medicine’ for patients suffering with IBD.” Micheal Anstey, Partner
Partner of CIC Paul Kinnon, CEO, PredictImmune added: “I am delighted with the level of investment secured in this latest round. It’s particularly gratifying to see our existing investors’ confidence in PredictImmune as they follow their initial investments and equally exciting to welcome new investors too. This investment will enable us to keep up the momentum, pushing on with our commercial expansion across the UK, Europe, the USA and rest of the world, whilst also allowing for the expansion and development of our product pipeline. It’s an exciting time to be part of PredictImmune, and as a team we are extremely motivated by both progress to date and our future objectives especially around enabling improved treatment choices in patients being diagnosed with IBD.”